Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P09237

UPID:
MMP7_HUMAN

ALTERNATIVE NAMES:
Matrin; Matrix metalloproteinase-7; Pump-1 protease; Uterine metalloproteinase

ALTERNATIVE UPACC:
P09237; Q9BTK9

BACKGROUND:
Matrix metalloproteinase-7, recognized by alternative names such as Matrin and Uterine metalloproteinase, is integral in the breakdown of various gelatins and fibronectin, alongside activating procollagenase. This underscores its essential function in the physiological and pathological processes of tissue remodeling.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Matrix metalloproteinase-7 offers a promising avenue for therapeutic intervention. Given its critical role in tissue remodeling, targeting this protein could lead to innovative treatments for conditions characterized by abnormal extracellular matrix dynamics.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.